ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 92 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 6.67 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,607,802 | -63.6% | 2,579,802 | -53.3% | 4.95% | -23.0% |
| Q2 2023 | $42,857,984 | +386.7% | 5,522,936 | +257.5% | 6.42% | +53.8% |
| Q1 2023 | $8,806,500 | +26.7% | 1,545,000 | +30.9% | 4.18% | +10.2% |
| Q4 2022 | $6,950,200 | +132.0% | 1,180,000 | +26.0% | 3.79% | +136.1% |
| Q3 2022 | $2,996,000 | – | 936,334 | – | 1.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |